Faisal Zain is a seasoned figure in the medtech ecosystem, bridging the gap between high-stakes venture capital and the gritty reality of medical device manufacturing. With years of experience driving innovation in diagnostics and treatment, he has a front-row seat to the tectonic shifts occurring in healthcare funding. As we navigate the complex financial waters of 2026, Zain offers a perspective shaped by both his time evaluating deals and his current role in the trenches of startup growth. This conversation explores the shifting dynamics of medtech investment, the resilience of exit markets, and how clinical validation has become the ultimate currency in an era dominated by artificial intelligence. We discuss the paradoxical rise in deal sizes despite lower total volumes and the critical role corporate venture arms now play in sustaining the early-stage pipeline.
Median deal sizes have climbed to $11.8 million even as overall deal value has dipped. How do you interpret this concentration of capital into fewer, larger checks?
It is a fascinating paradox that suggests a “flight to quality” rather than a flight from the sector. Even though we saw total deal value drop by 17.1% year-over-year in this first quarter of 2026, that is coming off a massive $16.1 billion high in 2025. The fact that the median deal size jumped from $10 million to $11.8 million tells me that investors are not losing interest; they are just becoming incredibly concentrated in their convictions. You can feel the tension in the room during pitch meetings where the focus has shifted from “can this work?” to “is this a category winner?” It is a leaner, more aggressive environment where the winners take the lion’s share, leaving smaller players to navigate a much tighter funding landscape.
Public market medtech companies are seeing their multiples compressed. Why has this cooling effect not completely frozen the private investment landscape?
I think many of us expected the de-rating of public companies to act as a handbrake on private venture deals. The iShares US Medical Devices ETF is down between 17% and 20% year-to-date, trading at levels far below the 2021 peaks, yet the private activity remains remarkably resilient. What I am seeing is that private investors are decoupling from public market volatility because the fundamental need for innovation in patient care has not slowed down. There is a certain grit in the medtech sector right now; even as public comps trade at lower multiples, the demand for high-performing, differentiated assets remains high. Strategics are still willing to pay a premium for technology that truly moves the needle in the clinic, regardless of what the broader stock market says.
Exit activity reached $4.1 billion in the first quarter of 2026, significantly buoyed by major IPOs and acquisitions. What does this tell us about the current appetite of strategic buyers?
The exit data is the silver lining that many people are overlooking right now. When you see nearly half of the entire 2025 exit value achieved in just the first three months of 2026, it signals that the window is swinging wide open for the right companies. The $2.2 billion surgical-robotics IPO from EdgeMedical sent a shockwave of confidence through the industry, proving that “big medtech” is still a viable public play. We are also seeing titans like Boston Scientific and Penumbra making $14.5 billion moves, while Danaher and Masimo close deals at $9.9 billion. These are not fire sales; these are strategic, full-price acquisitions of assets that have already navigated the hardest parts of the regulatory gauntlet and proven their worth in a clinical setting.
With AI absorbing a staggering 86% of US venture dollars in the first half of 2026, how can medtech startups avoid being completely crowded out?
It is an incredibly steep uphill battle when nearly nine out of every ten dollars are being funneled into the AI supercycle. You can almost hear the oxygen being sucked out of the room when you mention “hardware” or “clinical trials” to a generalist fund. The reality is that 89% of new fund commitments this year are going to established, seasoned managers who tend to be more risk-averse. For those of us in medtech, we have to lean into the “specialist” narrative and find those investors who understand that clinical demand is more durable than software hype. It is about proving that while AI is transformative, it still needs the physical interfaces and diagnostic tools—like the adaptive controllers I am currently developing—to actually reach the patient and improve outcomes.
Corporate venture arms from giants like Medtronic and J&J are becoming more active in early-stage rounds. How is this changing the capital structure for new founders?
This is one of the most significant structural shifts I have witnessed in the last few years. We used to rely on generalist VCs to “spray and pray” in the early rounds, but as they have pulled back, groups like Medtronic Ventures, J&J’s JJDC, and Philips Ventures have stepped into the breach. These corporate investors bring a level of clinical and regulatory sophistication that a traditional software-focused VC simply cannot match. It is a more disciplined form of capital; they are not just looking for a 10x exit, they are looking for a roadmap to clinical integration. For a founder, having a strategic partner early on can be a double-edged sword, but in this market, that specialized conviction is often the only thing keeping the lights on while generalists chase the next big multiple.
You have mentioned that it is currently a “buyer’s market” for VCs at the seed and Series A stages. What specific evidence must founders provide today to secure a check?
The days of raising on a “napkin sketch” and a dream are firmly behind us. Because there are fewer specialist funds left standing, the ones that remain can afford to be ruthlessly selective about who they back. I have seen firsthand that clinical validation and a bulletproof regulatory pathway are no longer “nice-to-haves”—they are the price of entry. You need to show concrete evidence of hospital demand, backed by data that proves your device solves a high-priority problem for administrators, not just doctors. Investors want to see that you have already walked the difficult path of de-risking the clinical side so they can focus strictly on the commercial scaling.
What is your forecast for medtech investment for the remainder of the year?
I believe we are entering a period of “productive scarcity” where, while the total dollar amounts might not return to the frothy peaks of years past, the quality of the companies being funded will be higher than ever. We will likely see more consolidation as smaller players are forced to merge, but the winners will emerge with stronger balance sheets and more rigorous clinical backing. The exit window will stay active because the aging population and the push for hospital efficiency are constants that do not fluctuate with market trends. By the end of 2026, I expect medtech to reclaim some of that “crowded out” capital as the initial AI hype settles into more practical, integrated healthcare applications that require real-world medical expertise.
